Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MET alterations in NSCLC—Current Perspectives and Future Challenges
Jordi Remón, Lizza E.L. Hendriks, Giannis Mountzios, et al.
Journal of Thoracic Oncology (2022) Vol. 18, Iss. 4, pp. 419-435
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Short-chain fatty acids in cancer pathogenesis
Mark A. Feitelson, Alla Arzumanyan, Arvin Medhat, et al.
Cancer and Metastasis Reviews (2023) Vol. 42, Iss. 3, pp. 677-698
Open Access | Times Cited: 48
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
Vincent D. de Jager, Wim Timens, Arnaud Bayle, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100838-100838
Open Access | Times Cited: 25
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Cancer Discovery (2024) Vol. 14, Iss. 8, pp. 1440-1456
Open Access | Times Cited: 14
Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET
Shengkai Xia, Wenzhe Duan, Mingxin Xu, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
Exploring Cellular Plasticity and Resistance Mechanisms in Lung Cancer: Innovations and Emerging Therapies
Caiyu Jiang, Shenglong Xie, Kegang Jia, et al.
Journal of Pharmaceutical Analysis (2025), pp. 101179-101179
Open Access | Times Cited: 1
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
Lorenzo Foffano, Elisa Bertoli, Martina Bortolot, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 583-583
Open Access | Times Cited: 1
Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trial
Yang Xia, Panwen Tian, Mo Zhou, et al.
EClinicalMedicine (2025) Vol. 81, pp. 103099-103099
Closed Access | Times Cited: 1
Almonertinib-induced interstitial lung disease in an NSCLC patient co-harboring EGFR Ex19del mutation and MET de novo amplification: a case report and literature review
Wenjing Yang, Lin Shi, Hao Wang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access | Times Cited: 1
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Yiming Qi, Jing Li, Sisi Lin, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
Calogera Claudia Spagnolo, Giuliana Ciappina, Elisa Giovannetti, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10119-10119
Open Access | Times Cited: 13
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
Tejas Patil, Alyse Staley, Yunan Nie, et al.
JTO Clinical and Research Reports (2024) Vol. 5, Iss. 2, pp. 100637-100637
Open Access | Times Cited: 5
Advancements in NSCLC
Jianan Xu, Lin Tian, Wenlong Qi, et al.
American Journal of Clinical Oncology (2024)
Open Access | Times Cited: 5
Revealing underlying regulatory mechanisms of LINC00313 in Osimertinib-resistant LUAD cells by ceRNA network analysis
Dandan Ding, Chenguang Xu, Jufeng Zhang, et al.
Translational Oncology (2024) Vol. 43, pp. 101895-101895
Open Access | Times Cited: 4
Application of a macrocyclization strategy in kinase inhibitor development
Kun Xing, Shujun Li, Jing Li, et al.
Acta Materia Medica (2025) Vol. 4, Iss. 1
Open Access
Intrapleural injection of Folactis promotes regression of malignant pleural effusion: a case of malignant pleural mesothelioma and the review of literatures
Naiqing Ding, Shu Su, Baorui Liu, et al.
Research Square (Research Square) (2025)
Closed Access
Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model
Gang Fang, Zhipeng Pi, Yu An, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Diagnostic and prognostic values of tsRNAs in lung cancer: a meta-analysis
Cheng Tang, Su‐Xia Sun, Chao Gu, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer
Hang Lin, Lingzhi Qu, Hudie Wei, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the EGFR Gene
Marcin Nicoś, Anna Sroka‐Bartnicka, Ewa Kalinka‐Warzocha, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 563-563
Open Access
The expression and functional role of proline-rich 15 in non-small cell lung cancer
Yong Ji, Han Zhang, Fuxing Gong, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
An optimized NGS Protocol for Detecting De Novo MET Amplification in NSCLC: Prognostic and Therapeutic Implications
Simon Cabello‐Aguilar, Julie A. Vendrell, Solène Evrard, et al.
Laboratory Investigation (2025), pp. 104117-104117
Closed Access
Current Biomarkers in Non-Small Cell Lung Cancer—The Molecular Pathologist’s Perspective
Konrad Steinestel, Annette Arndt
Diagnostics (2025) Vol. 15, Iss. 5, pp. 631-631
Open Access
Targeted Therapy: New Targets, Prospects and Clinical Use
Viktoriya R. Kuryanova, Feruza B. Guseinova, Aigerim E. Nurkeldina, et al.
Russian Journal of Oncology (2025)
Open Access
The Potential Role of C4 MYH11+ Fibroblasts and the MDK-SDC2 Ligand-Receptor Pair in Lung Adenocarcinoma: Implications for Prognosis and Therapeutic Strategies
H. Jia, Yanjie Bian, Jie Yuan, et al.
Translational Oncology (2025) Vol. 55, pp. 102364-102364
Closed Access
The impact of gut microbial short-chain fatty acids on colorectal cancer development and prevention
Boobalan Thulasinathan, Kanve N. Suvilesh, Sumanas Maram, et al.
Gut Microbes (2025) Vol. 17, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top